Santhera Pharmaceuticals Holding AG (SPHDF)
Santhera Pharmaceuticals Holding AG operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Pratteln, BL, CH. The stock last traded at $23.25, up 0.00% on the session, giving a market capitalisation of $344.8M. On trailing twelve-month figures it carries a trailing P/E of -4.16, a net margin of -63.8%. Its beta of -0.28 implies it has historically moved less than the broad market.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG is most often compared with the following Healthcare names: